Review
Version 1
Preserved in Portico This version is not peer-reviewed
The Immune System – Friend or Foe for Adenovirus Based Therapies?
Version 1
: Received: 25 May 2024 / Approved: 27 May 2024 / Online: 27 May 2024 (08:40:29 CEST)
A peer-reviewed article of this Preprint also exists.
Wallace, R.; Bliss, C.M.; Parker, A.L. The Immune System—A Double-Edged Sword for Adenovirus-Based Therapies. Viruses 2024, 16, 973. Wallace, R.; Bliss, C.M.; Parker, A.L. The Immune System—A Double-Edged Sword for Adenovirus-Based Therapies. Viruses 2024, 16, 973.
Abstract
Pathogenic adenovirus (Ad) infections are widespread but typically mild and transient, except in the immunocompromised. As vectors for gene therapy, vaccine and oncology applications, Ad based platforms offer advantages including ease of genetic manipulation, scale of production and well established safety profiles, making them attractive tools for therapeutic development. However, the immune system often poses a significant challenge that may need to be overcome for adenovirus based therapies to be truly efficacious. Both pre-existing anti-Ad immunity in the population as well as the rapid development of an immune response against engineered adenoviral vectors can have detrimental effects upon the downstream impact of an adenovirus-based therapeutic. This review focusses on the different challenges posed, including pre-existing natural immunity and anti-vector immunity induced by a therapeutic, both in context of the innate and adaptive immune responses. We summarize different approaches developed with the aim of tackling these problems, as well as their outcomes and potential future applications.
Keywords
Adenovirus; Vector; Immunity; T-cell; Antibody; Seroprevalence; Evasion
Subject
Biology and Life Sciences, Immunology and Microbiology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
